Elevance Health Inc. (ANTM)
NYSE: ANTM
· Real-Time Price · USD
482.58
12.71 (2.71%)
At close: Jun 28, 2022, 6:00 AM
Elevance Health Revenue Breakdown
| Period Ending | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|
| IngenioRx Segment Revenue | 12.78B | 10.38B |
| IngenioRx Segment Revenue Growth | +23.04% | n/a |
| Other Segment Revenue | 10.25B | 2.15B |
| Other Segment Revenue Growth | +376.08% | n/a |
| Government Business Segment Revenue | 82.92B | 36.7B |
| Government Business Segment Revenue Growth | +125.94% | n/a |
| Commercial Specialty Business Segment Revenue | 38.81B | 71.57B |
| Commercial Specialty Business Segment Revenue Growth | -45.78% | n/a |
| Segment Eliminations Revenue | -20.47B | n/a |
| Segment Eliminations Revenue Growth | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 4.27B | 4.34B | 4.22B | 3.95B | 3.82B | 3.92B | 4.32B | 5.3B | 4.05B | 3.78B | 3.5B | 3.42B | 3.28B | 3.17B | 3.62B | 3.55B | 3.43B | 3.43B | 3.39B | 3.01B | 3.05B | 3.19B | 3.26B | 3.12B | 2.97B | 3.2B | 3.27B | 3.08B | 3.04B | 3.15B |
| Selling, General, and Administrative Revenue Growth | -1.66% | +2.82% | +6.99% | +3.27% | -2.65% | -9.10% | -18.61% | +31.12% | +7.01% | +7.97% | +2.46% | +4.27% | +3.54% | -12.49% | +2.03% | +3.44% | -0.01% | +1.03% | +12.70% | -1.40% | -4.31% | -2.23% | +4.46% | +5.24% | -7.22% | -2.09% | +6.10% | +1.30% | -3.32% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue | 2.43B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 330M | 323.6M | 318.2M | 353.5M | 347.9M | 345.5M | 348.6M | 351.6M | 338.5M | 351.5M | 349.9M | 350M | 359.1M | 363.8M | 368.2M |
| Sales and Marketing Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100.00% | +1.98% | +1.70% | -9.99% | +1.61% | +0.69% | -0.89% | -0.85% | +3.87% | -3.70% | +0.46% | -0.03% | -2.53% | -1.29% | -1.20% | n/a |